Form 4: Director Arthur Golden Buys TTRX Shares

Turn Therapeutics Director Arthur Golden increased his stake in the company by purchasing 9,868 shares of common stock at a weighted average price of $3.44.

Summary

• Arthur F. Golden, a Director of Turn Therapeutics Inc. (TTRX), acquired 9,868 shares of common stock.
• The transaction occurred on November 24, 2025.
• The shares were purchased at a weighted average price of $3.44, with individual transaction prices ranging from $3.25 to $3.50.
• Following this transaction, Mr. Golden beneficially owns 60,602 shares of Turn Therapeutics Inc. common stock.
• The purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: A director's purchase of company stock, especially through a Rule 10b5-1 plan, typically signals confidence in the company's future performance and valuation.

Positives

• A director increasing their stake in the company can signal confidence in the company's future prospects and valuation.
• The purchase was executed through a Rule 10b5-1 plan, suggesting a planned investment decision rather than a reactive one.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, an insider purchase by a director can be interpreted as an implicit positive outlook on the company's future performance and valuation.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It reflects an individual director's investment decision within Turn Therapeutics Inc.

Comparison to Industry Standards

• This filing is a standard insider transaction report and does not contain information for direct comparison to specific industry benchmarks, projects, or competitor results. Insider purchases are generally viewed positively, but their significance depends on the size relative to the insider's total holdings and the company's market capitalization.

Related Party Transactions

• The transaction itself is a related party transaction, involving a director purchasing company stock.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive signal of confidence in the company's prospects, potentially influencing investor sentiment.

Key Dates

Recommendation

While insider buying is a positive signal, a single transaction by one director, even if substantial for that individual, typically warrants a 'hold' recommendation rather than a 'buy' without further fundamental analysis of the company's financials, strategic outlook, and broader market conditions. It indicates confidence but isn't a standalone reason for a strong buy.

Keywords

Turn Therapeutics Inc., TTRX, Arthur Golden, Insider Trading, Stock Purchase, Director, Form 4, Equity Acquisition, Beneficial Ownership, Rule 10b5-1